THE APEX TIMES
Shares of Coinbase slid after Morgan Stanley cut its rating to Underweight and reduced its price target, saying confidence in an earnings rebound has weakened.
Coinbase shares fell about 4% on Monday, Nov. 2, after Morgan Stanley downgraded the cryptocurrency exchange operator and lowered its price target. The move reflected a more cautious view of the pace and durability of Coinbase’s earnings recovery, according to the market report.
Morgan Stanley cut Coinbase’s rating to Underweight and reduced its price target by 53% to $120, the report said. In explaining the rationale, the firm pointed to a deterioration in “confidence in the earnings recovery,” suggesting its earlier assumptions about the company’s post-downturn trajectory have become less certain.
Coinbase’s business is closely tied to market conditions in digital assets, particularly trading activity and volatility. When retail and institutional investors are more active, trading volumes typically rise and fee income can improve. When sentiment cools or volumes decline, revenue and margins can come under pressure, which often drives sharper analyst reactions than in more diversified financial services businesses.
The report did not provide additional specifics about what changed within Coinbase’s fundamentals, such as guidance, operational metrics, or a new regulatory development. Instead, the focus was on the sell-side model’s updated outlook for earnings recovery, implying that either near-term earnings visibility has declined or key drivers are no longer expected to improve as quickly.
Morgan Stanley’s downgrade also comes at a time when investors are continuing to evaluate whether the sector’s normalization will translate into steadier, more predictable revenue for large exchanges like Coinbase. For exchanges, the path to an “earnings recovery” depends on multiple moving parts, including trading volumes, product mix, and the broader willingness of customers to transact in crypto.
A market-moving analyst cut can matter even without new company disclosures, because it often indicates a shift in expectations for future results. In this case, the combination of a rating cut and a large price-target reduction indicated that the firm’s downside case had gained traction relative to its prior view.
What remains unclear from the report is the underlying detail behind the confidence shift. The article did not cite whether Morgan Stanley changed assumptions about transaction-based revenue, costs, regulatory risk, or competition, nor did it reference any Coinbase-specific update delivered around the same time.
For market watchers, the next items to monitor are whether Coinbase provides fresh commentary on revenue trends and operating leverage, and whether additional analysts adjust their models in response to the downgrade. Confirmation of improving earnings momentum would likely be the counterweight to the “deteriorated confidence” framing highlighted by Morgan Stanley.
Greg Penner, Walmart’s chairman, and his wife Carrie Penner have reportedly added Spanish soccer club Valencia CF to their portfolio, alongside stakes in major U.S. sports teams.
In comments highlighted from its latest earnings call, Palantir said accelerating “sovereign AI” demand and continued deployment activity are driving an improved view for 2026, with growth tied to both U.S. commercial customers and defense programs.
In a new investor letter released as part of its “Thematic Growth Strategy,” Mott Capital pointed to Microsoft’s fiscal fourth-quarter results and reported that its strategy was up 9.01% year-to-date.
Despite a high-profile warning that China’s open-source AI model ecosystem could be used to steer demand toward domestic chips, investors bid up major semiconductor names on Tuesday.
With biotech investors calibrating expectations across earnings and clinical milestones, Moderna gained momentum before its results, Pfizer’s stock eased even as the company improved its guidance, and Merck declined amid a new late-stage trial update.
In a market session marked by weakness early in the day, Palantir shares gained ground after trading off their lows. Chip stocks outperformed, while a broader set of investors focused on insurance names framed as potential “entry points.”
After a third-quarter beat and an upgraded outlook, Pfizer’s strategy pitch centered on major dealmaking. A portfolio manager cautioned that the real proof will arrive later.
The company says it has put more than $10 billion into Kansas since 2010 and credits education and upskilling efforts with growing local employment opportunities.
Palantir (PLTR) reported results that beat Wall Street expectations, but the stock fell in premarket trading after investors appeared to question what the quarter’s contract trends imply for the company’s near-term outlook.
The Pershing Square founder questioned the market’s current price swings, attributing them to speculative trading and leverage, while naming several large consumer and financial-services companies he still views as durable holdings.
